Hypercholesterolemia – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Hypercholesterolemia – Pipeline Review, H2 2019’, provides an overview of the Hypercholesterolemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia

– The report reviews pipeline therapeutics for Hypercholesterolemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hypercholesterolemia therapeutics and enlists all their major and minor projects

– The report assesses Hypercholesterolemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hypercholesterolemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

AD Pharmaceuticals Co Ltd

AFFiRiS AG

Akcea Therapeutics Inc

Amryt Pharma Plc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

Beijing Mabworks Biotech Co Ltd

BioLingus AG

CardioPharma Inc

Centeer BioTherapeutics Ltd Co

Chong Kun Dang Pharmaceutical Corp

Civi Biopharma Inc

Cumberland Pharmaceuticals Inc

CymaBay Therapeutics Inc

Daewoong Co Ltd

Delivra Corp

Dogma Therapeutics Inc

Draupnir Bio Aps

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Golden Biotechnology Corp

Hingez Therapeutics Inc

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

Kadmon Corp LLC

Kyorin Pharmaceutical Co Ltd

LIB Therapeutics LLC

Lipigon Pharmaceuticals AB

LipimetiX Development Inc

Luye Pharma Group Ltd

Madrigal Pharmaceuticals Inc

Medlab Clinical Ltd

Novo Nordisk AS

Nyrada Inc

OliPass Corporation

Pfizer Inc

Portola Pharmaceuticals Inc

Precision Biosciences Inc

Progenra Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Repair Biotechnologies Inc

Shanghai Junshi Bioscience Co Ltd

Shenzhen HighTide Biopharmaceutical Ltd

Shifa Biomedical Corp

The Medicines Company

Viking Therapeutics Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Zhejiang Teruisi Pharmaceutical Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Hypercholesterolemia Overview 6

Hypercholesterolemia Therapeutics Development 7

Hypercholesterolemia Therapeutics Assessment 18

Hypercholesterolemia Companies Involved in Therapeutics Development 26

Hypercholesterolemia Drug Profiles 42

Hypercholesterolemia Dormant Projects 175

Hypercholesterolemia Discontinued Products 181

Hypercholesterolemia Product Development Milestones 183

Appendix 196

List of Tables

List of Tables

Number of Products under Development for Hypercholesterolemia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hypercholesterolemia – Pipeline by 3SBio Inc, H2 2019

Hypercholesterolemia – Pipeline by AbbVie Inc, H2 2019

Hypercholesterolemia – Pipeline by AD Pharmaceuticals Co Ltd, H2 2019

Hypercholesterolemia – Pipeline by AFFiRiS AG, H2 2019

Hypercholesterolemia – Pipeline by Akcea Therapeutics Inc, H2 2019

Hypercholesterolemia – Pipeline by Amryt Pharma Plc, H2 2019

Hypercholesterolemia – Pipeline by Arrowhead Pharmaceuticals Inc, H2 2019

Hypercholesterolemia – Pipeline by AstraZeneca Plc, H2 2019

Hypercholesterolemia – Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2019

Hypercholesterolemia – Pipeline by BioLingus AG, H2 2019

Hypercholesterolemia – Pipeline by CardioPharma Inc, H2 2019

Hypercholesterolemia – Pipeline by Centeer BioTherapeutics Ltd Co, H2 2019

Hypercholesterolemia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019

Hypercholesterolemia – Pipeline by Civi Biopharma Inc, H2 2019

Hypercholesterolemia – Pipeline by Cumberland Pharmaceuticals Inc, H2 2019

Hypercholesterolemia – Pipeline by CymaBay Therapeutics Inc, H2 2019

Hypercholesterolemia – Pipeline by Daewoong Co Ltd, H2 2019

Hypercholesterolemia – Pipeline by Delivra Corp, H2 2019

Hypercholesterolemia – Pipeline by Dogma Therapeutics Inc, H2 2019

Hypercholesterolemia – Dormant Projects, H2 2019

Hypercholesterolemia – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Hypercholesterolemia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports